Close Menu

NEW YORK – OpGen announced on Tuesday that it has inked a definitive agreement with a US-based investor for a $25 million registered direct offering.

The unnamed healthcare-focused institutional investor is purchasing 2,784,184 shares of common stock and 5,549,149 prefunded warrants where each warrant is exercisable for one share of common stock, OpGen said. In a concurrent private placement, the company is issuing unregistered common share purchase warrants to purchase 4,166,666 shares of common stock.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.